Neuropilin-1 (NRP-1), a transmembrane glycoprotein acting as a co-receptor of VEGF-A, is expressed by cancer and angiogenic endothelial cells and is involved in the angiogenesis process. Taking advantage of functionalities and stereodiversities of sugar derivatives, the design and the synthesis of carbohydrate based peptidomimetics are here described. One of these compounds (56) demonstrated inhibition of VEGF-A165 binding to NRP-1 (IC50 = 39 µM) and specificity for NRP-1 over VEGF-R2. Biological evaluations were performed on human umbilical vein endothelial cells (HUVECs) through activation of downstream proteins (AKT and ERK phosphorylation), viability/proliferation assays and in vitro measurements of anti-angiogenic abilities. 50, 56, 61 and 69, which have the higher affinities for NRP-1 (Table 1) were selected for their biological evaluation on HUVECs. Binding of compounds to NRP-1 was evaluated by the activation of PI3K/AKT and MAPK downstream signaling pathways, through phosphorylation of AKT, a serine/threonine protein kinase and extracellular signalregulated protein kinases 1 and 2 (ERK1/2), respectively. Both are involved in NRP-1/VEGFR-2 signaling pathways. The cellular binding of the different compounds to NRP-1 led to a mean of 40% decrease of ERK phosphorylation (ratio ranging from 0.61 to 0.68, Figure 3A et 3B) compared to tuftsin (ratio of 0.88), the natural ligand of NRP-1. In contrast, an increase of AKT phosphorylation was observed for each ligand as well as for tuftsin. It should be noted that the most relevant effect was obtained for compound 56 (ratio 2.52), whereas compound 50 showed a lesser effect (ratio 1.56). Effects on HUVECs viability were measured by metabolic assay (WST) ( Figure 3C ). Modifications observed for signaling pathways ERK1/2 and AKT did not lead to detrimental effect on the viability of endothelial cells whatever the tested concentration.
Introduction
Angiogenesis or formation of new blood vessels requires the binding of signaling molecules, such as vascular endothelial growth factor (VEGF), which is one of the most specific and important growth factors involved in this process. 1,2 VEGF-A165 mediates its biological effects through receptors located on the endothelial cells, i.e. VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR). VEGF-A165 is overexpressed by a wide variety of human tumors and this overexpression has been correlated with invasion and metastasis. 3 Interestingly, Neuropilin-1 (NRP-1), a receptor protein firstly described in neuronal guidance, 4 is involved in a wide range of physiological and pathological processes including angiogenesis. 5 This transmembrane protein was found to be a co-receptor of VEGF-A165 acting together with VEGFR-2 via its NRP-1 b1/b2 domain, resulting in increased affinity of VEGF-A165 for the extracellular domain of VEGFR-2. 6 VEGF-A165 can also contribute to VEGFR-2/NRP-1 complex formation via its binding through two different sites for both NRP-1 and Moreover, independently of VEGFR-2, NRP-1 alone might transduce functional signaling as a result of VEGF binding. 8 is expressed on endothelial cells promoting tumor angiogenesis 6,9 and on tumor cells and has thus been identified as a potential target for anti-angiogenic therapies. 10, 11 This receptor could also be a mediator of choice for cancer imaging. Few attempts to use NRP-1 in cancer imaging via a [99mTc]-labelled peptide, 12 multifunctional nanoparticles engineered with gadolinium chelates as MRI contrast agents, 13 and fluoresceinlabeled peptides are reported in the literature. 14 More recently, NRP-1 targeting peptides were conjugated onto the surface of lipid microbubbles for molecular imaging of tumor angiogenesis. 15 Targeting NRP-1 with small molecules mimicking VEGF-A165 is not very advanced, because of difficulty to mimic proteinprotein interactions. Nevertheless, several peptides have been reported to modulate VEGF-A165/NRP-1 binding. The first crystal structure of the b1 domain of the human NRP-1 was determined by Lee et al. 16 The role of the loops at b1 domain of human NRP-1 as a target binding site for ligand interaction has also been highlighted by Vander Kooi et al. with their study of NRP-1 binding with tuftsin (TKPR), which is very similar to the VEGF-A165 C-terminus (DKPRR). 17 The C-terminal arginine of tuftsin contributes to the majority of interactions with NRP-1 and this was confirmed by a molecular modeling approach developed by Haspel et al. 18 The interaction of NRP-1-b1 domain with VEGF-A165 was recently elucidated by Parker et al. 19 Jia et al. have discovered a specific bicyclic peptide EG3287 antagonist of VEGF-A165 binding to NRP-1. 20 Heptapeptide ATWLPPR (A7R), selected by screening a phage display library was described as an effective antagonist and can be considered as a potent inhibitor of tumor angiogenesis. 21 targeting photodynamic therapy (PDT) using A7R as NRP-1 ligand associated with a porphyrinlike sensitizer has since been developed. 22 New peptides structurally related to VEGF-A165 exon-7 and -8 domains were recently designed and synthesized. 23 However, peptidic compounds could suffer from poor bioavailability and instability 24 and the design of new organic molecules such as peptidomimetic derivatives seems an attractive alternative. In connection with our ongoing program on the design of sugar-based peptidomimetics, we described a few years ago the design, synthesis and in vitro biological evaluation of sugar-based peptidomimetics targeting NRP-1. Interesting compounds were obtained and one hit compound was identified (compound 1, Chart 1a). 25 Simultaneously, a paper by Jarvis et al. described compound EG00229 as small molecule inhibitor of the NRP-1/VEGF-A165 binding and this molecule has recently shown in vivo activity towards cancer models (Chart 1a). 26 More recently, a fully nonpeptidic compound comprising phenylbenzimidazole and benzodioxane moieties linked by a stable carboxythiourea spacer was identified. 27 New antagonists structurally-related to this compound were synthesized and evaluated toward VEGF-A165/NRP-1 binding modulation. 28 Several drug-like compounds containing a common chlorobenzyloxy alkyloxy halogenobenzyl amine scaffold were identified by virtual screening for their efficient binding to NRP-1. 29 The objective of the present work was the molecular design and synthesis of new NRP-1 ligands inspired by compound 1. 25 The use of carbohydrates as scaffolds to construct bioactive compounds and peptidomimetics is a well-accepted concept since the pioneering works related to peptidomimetics of somatostatin. 30, 31, 32 We wanted to take advantage of functionalities and stereodiversities of sugar derivatives to develop new analogs of carbohydrate-based peptidomimetics. Thus, sugar scaffolds functionalizable at both ends and offering different spatial orientations for residues were investigated according to molecular modeling and the in vitro biological properties of the new ligands were evaluated.
Results and discussion
Sugar scaffolds A and B suitable for functionalization at both ends could arrange crucial residues in opposite spatial directions and were both investigated in this regard (Chart 1b). Firstly, compound 1 was modified stepwise, the importance of the two guanidine functions was studied and the effect of hydrocarbon linker lengths separating the guanidinium groups was explored (first series). A second series with an arginine anchored at C1 was developed according to docking study. In the meantime, synthetic compounds were used to get crystals of NRP-1/ligand complex. The binding affinity of new derivatives was performed by ELISA and the effects of the most potent ligands were evaluated on HUVECs through activation of downstream proteins, viability assays and in vitro angiogenic abilities. 
Synthetic Chemistry
The C-glycosidic scaffold A which was used for compound 1 synthesis was obtained from the known exo-glycal 2 available in excellent yield via a Wittig reaction on the D-gulono-1, 4-lactone. 33 In the same way, scaffold B was obtained from exo-glycal 3 directly available from the corresponding D-ribono-1, 4-lactone. The first series aimed at synthetizing new peptidomimetic compounds close to compound 1 structure. The impact of the spatial disposition of both guanidium groups and 2-(indolyl- 3yl) ethyl residue was evaluated by synthesizing a compound based on the sugar scaffold B. Moreover, while maintaining compound 1 central core (scaffold A) with the 2-(indol- 3-yl) ethyl residue at C1, the effect of the linker length between both guanidinium groups was considered. The replacement of one of the guanidium functions by a triazole moiety acting as a stable linker [34] [35] [36] was envisioned.
The synthetic pathway for the first series required the preparation of the key tosylates 8 and 24 (Scheme 1A and 1B). The known exo-glycal 2 was converted to C-glycoside 4 by stereoselective reduction of the double bond. 37 Subsequent saponification of 4 followed by coupling with tryptamine led to amide 6. Alcohol 7 was prepared by a multistep sequence including the selective removal of the exocyclic isopropylidene acetal under acidic conditions, NaIO4 mediated oxidative cleavage and reduction of the resulting aldehyde. The alcohol 7 was then converted in the corresponding tosylate 8 in excellent yield. In the same way, exo-glycal 3 was converted in C-glycoside 18. After changing acetate protecting group at O7 for a tertbutyldimethylsilyl ether, subsequent saponification of 20 led to the key acid 21 in good yield. Amide 22 was prepared by coupling with tryptamine. Removal of the tert-butyldimethylsilyl group was achieved by TBAF and the resulting alcohol was converted in tosylate 24 in 87% yield.
Refluxing tosylates 8 and 24 with different commercially available monoprotected diaminoalkanes (n = 2, 3 and 4 for 8 and n = 1 for 24, Scheme 1C) in a sealed flask led to intermediates 9, 10, 11 and 25. Free amines obtained in quantitative yields after removal of benzyloxycarbonyl group were treated with N,N'bis(benzyloxycarbonyl)-S-methylisothiourea 38 in DMF. Bisguanidinylated derivatives 12, 13, 14 and 26 were obtained in modest yields, resulting from the reaction of both primary and secondary amines. Finally, removal of protecting groups afforded the expected bis-guanidinoglycosides 15, 16, 17 and 27. Attempts to remove the 4,5-isopropylidene group under different acidic conditions were unsuccessful, the number of nitrogen atoms obviously preventing oxygen protonation required for acetal deprotection. On the basis of structure 1, we next focused our attention on the replacement of the guanidine function anchored on the secondary amine by a 1,2,3-triazole moiety bearing guanidylated arms (Scheme 2). This synthetic approach required the preparation of two guanidylated alkynes 28 and 29 obtained by a Mitsunobu reaction. The C-glycoside 30 bearing an azido group on C7 was obtained by reaction of sodium azide with tosylate 8. The synthesis of the 1,4-substituted-1,2,3-triazole moiety was next envisioned between azide 30 and alkynes 28 and 29 in a 1/1 H2O/CH2Cl2 mixture, which was the more appropriate solvent in this case. 39, 40 Compounds 31 and 32 were obtained in good yields. Removal of benzyloxycarbonyl protecting groups was achieved by hydrogenolysis and led to 33 and 34 in nearly quantitative yields. Removal of 4,5-isopropylidene protecting group by aqueous trifluoroacetic acid was performed and fully deprotected derivatives 37 and 38 were then obtained by hydrogenolysis. The synthetic plan for the second series implied the introduction of an L-arginine at C1 and the anchoring of a hydrophobic residue at C7. The coupling of C-glycosyl compound 5 with N  -nitro-L-arginine methyl ester led to amide 39 (Scheme 3A). The carboxylic acid and guanidinium function of arginine were successively deprotected by classical methods. We next investigated the impact of a more rigid system based on Cglycosylidene derivative obtained from exo-glycal 2 (Scheme 3B). To this end, using a method for methyl ester deprotection which did not affect the anomeric double bond was mandatory. This was achieved by using lithium iodide in pyridine. The resulting vinylic acid 41 was then coupled with L-arginine methyl ester without protection on its lateral chain. An isomerization of the double bond was observed and two isomers E/Z were obtained in an approximatively 1/1 ratio. This isomerization could obviously be attributed to reversible addition of HOBt on the anomeric carbon of activated exo-glycal, prone to 1, 4-additions. 33 At this point, the purification of the isomeric mixture was not possible by normal or reverse phase chromatography. This mixture was thus subsequently treated by lithium iodide in pyridine and reverse phase purification led to isolation of 42, which is the only one obtained as pure material.
Guided by published works [25] [26] [27] [28] highlighting the favorable impact of an hydrophobic group and docking studies pointing out the benefit of a supplementary chemical groups such as a phenyl (see 2.2), an aromatic residue was linked to C7 via a sulfonamide linkage. This required the preparation of the key intermediate tosylates 45 and 51 obtained from 44 and 19 (Scheme 3C). The selective removal of the exocyclic isopropylidene acetal of 4 under acidic conditions led to diol 43 subsequently transformed in alcohol 44. Substitution with sodium azide carried out in DMF led to azido derivatives 46 and 52 in 84 and 97% yields respectively. Catalytic hydrogenation afforded primary amines which were treated with benzene sulfonyl chloride in pyridine to give phenylsulfonamides 47 and 53 in good yields. We next managed the introduction of L-arginine at C1 and compounds 49 and 55 were obtained in 84% and 71% yields respectively. Finally, fully deprotected derivatives 50 and 56 were obtained in good yields after methyl ester and arginine side chain protection removal. Molecular modeling studies highlighted that presence of a negative or positive charge in para position on the aromatic ring could led to improved affinity (see 2.2). Taking into account preliminary inhibition results (see 2.3), we thus planned to functionalize 56 with substituents able to make additional hydrogen bonds or salt bridges in the receptor binding site. In this regard, an aminomethyl and a hydroxycarboxymethyl groups were selected (Scheme 4A and 4B). Starting from azido derivative 52, the coupling of the 4-bromomethylphenylsulfonyl chloride in dichloromethane led to the bromomethyl derivative 57. Compound 58 was then obtained in quantitative yield by nucleophilic substitution of the bromine with sodium azide in DMF. Coupling with L-arginine methyl ester and treatment with lithium hydroxide gave acid 60 in 86% yield for two steps. Finally, fully deprotected derivative 61 was obtained by catalytic hydrogenation of azido group. The synthesis of compound 63 required a slightly modified pathway, notably the saponification of methyl ester 52 before introduction of the sulfonyl chloride. After saponification with lithium hydroxide and catalytic hydrogenolysis of azido ester 52 with Pd/C, sulfonamide 62 was obtained by reaction with methyl 2-(4-chlorosulfonylphenyl)acetate. Coupling with L-arginine methyl ester and removal of both methyl ester functions led to the diacid 63. In connection with ongoing work in our group 41 concerning conjugation of biomolecules with sugar derivatives, compound 56 was coupled with the 2-azidoethyl-6-fluoro--D-glucopyranoside 68. Indeed, 2-azidoethyl-6-fluroglycosides are easily prepared 41b and are valuable prosthetic groups for fast and easy labelling of peptides or peptidomimetics by copper(I)-catalyzed azidealkyne cycloaddition. 36 To this end, derivative 64 was obtained by coupling 4-iodobenzenesulfonyle chloride (Scheme 4C). Sonogashira reaction was then performed with trimethylsilylacetylene. Subsequent removal of methyl ester and trimetysilyl protecting groups was performed and led to alkyne 66 in good yield. As described above, L-arginine methyl ester was introduced on C1 position. The copper(I)-catalyzed azide-alkyne cycloaddition was performed between alkyne 67 and azide 68 and led to fluoro derivative 69 in 77% yield. Crystals were obtained in presence of compound 56. They exhibited the same tetragonal crystal packing as those of the free protein fragment 16 but the resolution of the data was substantially improved (1.45 vs. 1.90 Å, see SI Table S1 ). The structure revealed that the crystallized protein did not form a complex with the synthesized compound. Instead, a bicine molecule was found in the VEGF-A165 binding cleft ( Figure 1a ). The bicine sodium salt was used as pH buffer in the crystallization condition. A sodium atom in octahedral geometry was also found, it is interacting with a bicine hydroxylgroup and five water molecules. The ternary amine and carboxylic group of bicine are hydrogen-bonded to the Tyr353 and Thr349 side-chains, respectively. The bicine molecule also formed interactions with residues of a symmetry related protein molecule (see SI Figures S1, S2). Several methylene hydrogen atoms of bicine form hydrophobic H...Pi and H...H interactions with Tyr297 and Trp301. The Asp320 residue, which forms an important salt bridge with an arginine in the NRP-1/VEGF-A165 biological complex 19 and in the complex with EG00229 26a was in the present structure in interaction with the Na + ion through a water bridge. This NRP-1-b1/bicine complex highlighted the conservation of the anchoring residues of the VEGF-A165 binding cleft. The crystal structures of NRP-1-b1/ligand complexes provided us additional informations to guide an in silico optimization of our synthesized ligands. We undertook optimization of structures by molecular modeling and compound 40 was chosen as a starting point. It appeared from preliminary docking calculations that all the obtained poses of the first docked molecule 40 were anchored within the binding site in the same way as the PDB 3I97 EG00229 ligand (Chart 2), namely through a strong ionic interaction involving the guanidinium moiety of the ligand and the protein Asp320. It should be noted that the best pose obtained for the EG00229 compound itself was exactly similar to the pose found in the X-ray structure, therefore validating our docking procedure. 26a Depending on poses, several additional favorable Hbond interactions were detected with residues containing hydroxyl groups such as Tyr353, Tyr297, Thr349 and Ser346. It is also noteworthy that these interacting residues are similar to those found in the bicine/NRP1-b1 structure. The best docking poses of 40 and EG00229 were next refined using short 10 ns molecular dynamics runs. The analysis of the different trajectories confirmed the robustness of the ligand guanidine…Asp320 salt bridge which was observed as stable during all simulations (Figure 2a ). A supplementary ionic interaction was also established after several ns of the MD simulations stabilizing the position of the arginine terminal-carboxyl of the ligands with the ammonium group of Lys351 ( Figure 2b ). Such an interaction between an exposed Lys side chain with the ligand, while in competition with the solvent, is nevertheless observed in many protein/ligand complexes such as the kinases. 42 In the case of the X-ray structure complex with EG00229, the presence of an intramolecular hydrogen bond involving the arginine terminal-carboxyl of EG00229 precluded an interaction with Lys351 in the complex. Comparing the behavior of 40 and EG00229 during these MD simulations showed that 40 could present additional stabilizing interactions on the condition to add supplementary chemical groups such as a phenyl moiety at the C7 position. Furthermore, both C6 stereoisomers were considered (scaffolds A and B, Chart 1). Consequently, we checked this hypothesis with both new synthesized compounds 50 (scaffold A) and 56 (scaffold B) which were submitted to the same docking and short MDs protocols. Comparing the interactions found during these MD simulations between 40, 50 and 56 clearly showed that compound 56 should be a better compound, this behavior being mostly due to π-π and π-cation additional interactions coming from the added phenyl ring with Tyr297 or Lys347 side chains (Figure 1b and 1c) . These interactions are observed during most of the simulation. According to these simulations, it can also be suggested that expanding the phenyl group with positive or negative charged groups (compounds 61 and 63) or with longer chains such as the one found in 69 could give the possibility to attract the Lys347 or Glu348 or Glu312 charged side chains (Figure 1d ).
Crystallographic study and molecular modeling

Biological evaluation
The binding of new derivatives to recombinant NRP-1 protein was determined using a competition assay initially described by Tirand et al. 43 Binding of compounds to NRP-1 was assessed using biotinylated VEGF-A165 (bt-VEGF-A165), in competition, or not, with an excess of compounds or non labelled VEGF-A165. Tuftsin was used as positive control (IC50 = 25 µM). A preliminary screening with 100 µM inhibitor concentrations was performed. For the most active compounds (inhibition >40% at 100 µM, Table 1), the IC50 value was determined with concentrations ranging from 10 µM to 500 µM. VEGF might crosslink VEGF-R2 and NRP-1 26 and it was recently demonstrated that NRP-1 could interact directly with VEGF-R2 without VEGF. 6b Thus, it was appropriate to compare binding of new derivatives with NRP-1 and VEGF-R2. The binding of the four best compounds to VEGF-R2 (KDR) were evaluated using a similar competition assay, showing the selectivity for NRP-1 (Table 2 ). In order to determine the biological activity of compounds on endothelial cells, human umbilical vein endothelial cells (HUVECs) expressing VEGF-R1, VEGF-R2 and NRP-1 were used. It was previously demonstrated that the inhibition of VEGF-A165 binding to NRP-1 had effect on VEGF-A165 ability to activate VEGFR-2 (KDR). 20 Compounds The anti-angiogenic properties were evaluated through the in vitro ability of HUVECs to form tubules-like capillaries on a basement matrix ( Figure 4 ). In vitro angiogenesis assay using HUVEC seeded on Matrigel is a well-established assay to screen the angiogenic effect of many substances. Among the tested compounds, 69 demonstrated a wide effect on tubules formation. The effects of 69 could be compared to tuftsin and were relatively close to those observed with bevacizumab, a humanized anti-VEGF monoclonal antibody used nowadays in clinic for cancer therapy and used here as positive control. Inhibition of tubules-like capillaries was also observed to a lesser extent with compound 61. The junctions number. B segments number C as well as the total segments length D were quantified by Angiogenesis Analyser for ImageJ. nt, non treated; tuf, tuftsin; beva, bevacizumab. Results are presented as mean ± standard error of the mean of three independent experiments and p<0.05 was considered to be statistically significant.
Discussion
The first series of analogs exhibited a VEGF-A165/NRP-1 inhibition which did not exceed 40%, except for compound 17. The effect of the linker length of separating both guanidium functions was difficult to evaluate, since compound 15 inhibited very weakly VEGF-A165/NRP-1 binding (entry 2, Table 1 ), while a modest activity was observed for 16 and 17 at 100 µM concentration (entries [3] [4] . Compound 27, based on sugar scaffold B and functionalized in the same manner as compound 1 was less active than this latter, suggesting a non-adapted spatial disposition of crucial residues (entry 5). Compounds 34, 33 and the corresponding diols 38 and 37 showed a weak affinity for NRP-1, suggesting that triazole moiety could be too rigid linker and deleterious for binding (entries 6-9).
The second series showed general binding inhibition properties higher than 40% at 100 µM, excepted for compound 63. Arginine anchored at C1 was beneficial for NRP-1 binding, as shown for compound 50 and 56 (entries [12] [13] . Compound 56 based on scaffold B showed a 67% binding inhibition at 100 µM and an IC50 of 39 µM, this result being in agreement with in silico predictions (see 2.2). However, the presence of amino-methyl and hydroxy-carboxymethyl groups recommended by molecular modeling was not beneficial for binding (entries [14] [15] ), suggesting that the added chains were not long enough. Compound 69 obtained by conjugation with the 6-fluoroglycoside 68 displayed a 70% binding inhibition at 100µM and an IC50 of 70 µM, pointing out that the presence of the sugar derivative was not deleterious for NRP-1 binding.
The biological properties of the compounds having the higher affinity were evaluated on HUVECs firstly through the downstream signaling pathways of NRP-1. All the compounds induced a similar change of ERK1/2 signaling pathways, which did not really impact the viability of endothelial cells even with a high concentration of 200 µM. Nevertheless, some compounds showed a significant effect on angiogenesis network formation. Unexpectedly, while compound 69 did not have the best affinity (IC50 = 69 µM), this latter demonstrated the most efficient properties toward inhibition of tubules formations. On the contrary, compound 56, the most affine compound (IC50 = 39µM), showed a lack of antiangiogenic effect, which could be explained by the significant increase of AKT phosphorylation with this compound (ratio 2.52). Indeed, AKT signaling pathway is well known to induce cell survival that limit the endothelial cell network remodeling during angiogenic process. The complexation of NRP-1 with its two well-known co-receptors, VEGFR and plexin (receptor of semaphorins), which have opposite effect on endothelial cell migration and tubulogenesis, 46 could explain the results obtained with the different compounds. Indeed, the binding domains for semaphorin (a1/a2) are relatively close to the VEGF-A165 binding domains (b1/b2) and some compounds could also interact partially with a1/a2 semaphorin domains. Compounds 50, 56 and 61 which induced a slight invasive effect, could modify the signaling pathway involving the plexin/semaphorine/NRP-1 ternary complex. On the contrary, compound 69 seems to be more specific of the b1/b2 domains of VEGF due to its similar effect to tuftsin and to a lesser extent to bevacizumab. Consequently, despite a good affinity for NRP-1 attested by decrease of MAPK-induced activation, an evaluation of all signaling pathways regulated by NRP-1 47 could allow elucidation of the different cellular effects observed with the tested compounds.
Conclusion
We have synthesized two series of carbohydrate-based peptidomimetics targeting NRP-1. The design of these ligands was based on rational modification of compound 1 to enhance binding interaction. Compound 56 inhibited VEGF-A165/NRP-1 binding with an IC50 = 39 µM, which is in the range of activity described by others working on NRP-1 inhibitors. Compound 56 demonstrated specificity for NRP-1 over VEGF-R2 binding more than 10-fold. No cytotoxic effects on HUVECs proliferation or viability were measured for all tested compounds. Interestingly, compound 69 (IC50 = 69µM) demonstrated a significant effect on tubules formation which could be compared to tuftsin and to a lesser extent to bevacizumab without promoting the endothelial cells migration. In addition to its use as a potential anti-angiogenic compound, this compound could be envisaged to target cells overexpressing NRP-1 as cancer cells.
Experimental section
Chemistry
Reagents, general methods, experimental procedures for synthesis and characterizations of all intermediates are given in SI. Compounds 2-6 have been prepared according to literature procedures. 25 
N  -[2-C-[2,3-O-(1-methylethylidene)-5-benzosulfonylamino--D-galactofuranosyl]carbonymethyl)]-Larginine methyl ester 50
To a solution of 49 (500 mg, 0.85 mmol) in THF (20 mL) and water (3 mL) was added LiOH (65 mg, 2.55 mmol, 3 eq.) and the mixture was stirred until completion of the reaction monitored by tlc. Amberlite ® IR-120 was added until pH = 3-4 and the mixture was filtered off. The solvent were evaporated and the obtained carboxylic acid was solubilized in MeOH (20 mL) and Pd/C (10%) (40% w/w) was added. After stirring under H2 atmosphere (40 psi) until completion of the reaction, the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. 
1. 1. N  -[2-C-[2,3-O -(1-methylethylidene)-5-benzosulfonylamino- -Dribofuranosyl]carbonylmethyl)]-L -arginine methyl ester 56
Prepared starting from 55 (150 mg, 0.26 mmol) following procedure described for 50 Yield: 70% (94 mg). 
3-O -(1-methylethylidene)-5-[((4-aminomethyl)benzo)sulfonylamino]- -Dribofuranosyl]carbonymethyl)]]-L -arginine methyl ester 61
To a solution of 60 (80 mg, 0.14 mmol) in MeOH (5 mL), was added Pd/C (10%) (8 mg, 10% w/w). After stirring under H2 atmosphere (15 psi) until completion of the reaction, the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. 
1. 2. Compound 69
To a solution of alcyne 67 (33 mg, 0.04 mmol, 1 eq.) and azido sugar 68 (15 mg, 0.04 mmol, 1 eq.) in a water/tBuOH mixture (0.5 mL/0.5 mL) were added sodium ascorbate (2.4 mg, 0.008 mmol, 0.2 eq.) and Cu(OAc)2 (1.2 mg, 0.004 mmol, 0.1 eq.). The solution turned progressively pale green and the mixture was stirred at room temperature until completion of the reaction (the blue color reappeared). Chelex ® resin (100 mg) was then added to the solution and the suspension was stirred until the solution became colorless. The resin was filtered off and the solvent were removed under reduced pressure. The crude was purified by column chromatography (C-18 silica gel, H2O/MeOH) and lyophilized to provide 69 (37 mg, 77%). 
Molecular modeling
The structures of the investigated compounds were prepared according to the CORINA 48 (for the 3D conformers) and MOPAC 49 softwares (for the atomic charges). The chemicals were firstly docked using the GOLD software (see SI for details). 50 The protein target was the 3D structure of the b1 domain of NRP-1 as solved by X-ray when bound with the small molecule EG00229 26 (pdb code 3I97).
Biocrystallography
A crystallization screening of NRP-1-b1 fragment including a 6-His tag at the N-terminus was carried out in presence of compounds 27, 40, 50 and 56 (see SI for details). The crystal structure has been deposited at the Protein Data Bank 51 with code 5C7G.
Biological Assay
General procedure for receptor binding assays: The binding of new derivatives to recombinant NRP-1 protein was determined using a competition assay initially described by Tirand et al. (see details in SI). 43
Supplementary Material
Experimental procedures for synthesis and characterizations of all intermediates and copies of 1 H and 13C NMR spectra, crystallographic summary of NRP-1/bicine structure, protein production and purification, biological assays and experimental procedures for molecular modeling and biocrystallography. This material is available free of charge via the Internet at Abbreviations MRI, magnetic resonance imaging; AKT, serine/threonine protein kinase; ERK1/2, extracellular signal-regulated protein kinases 1 and 2. Table S1 . Crystallographic summary of NRP-1/bicine structure Figure S1 . Ribbon view of the NRP-1 b1 dimer in the tetragonal crystal 
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3,6-Anhydro-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-hydroxy-L-galacto-heptonamide 7
To a stirred solution of 6 (3.73 g, 8.40 mmol) in methanol (180 mL) at 0°C was added dropwise an aqueous solution of 1N HCl (60 mL). After stirring at room temperature until completion of the reaction, sat. aq. NaHCO3 was added until pH = 7. Half of the solvent was removed under vacuum and the product was extracted with CH2Cl2 (3 x 100 mL). The organic layer was dried over MgSO4, filtered and the solvent was evaporated. To a stirred solution of this diol in methanol (180 mL) was added NaIO4 (3.59 g, 16.8 mmol, 2 eq.) under argon. After stirring at room temperature until completion of the reaction, the solvent was removed by half in vacuo. The mixture was diluted with CH2Cl2 (200 mL). The organic layer was washed with water (3 x 75 mL), dried over MgSO4, filtered and the solvent was removed under reduced pressure. The product was used without further purification.To a stirred solution of the obtained aldehyde in MeOH (190 mL) was added NaBH4 (320 mg, 8.40 mmol, 1 eq.) at 0°C. After 1 h at room temperature, the solvent was removed under reduced pressure. The residue was diluted in CH2Cl2 (100 mL) and the organic layer was washed with a solution of 1N HCl (30 mL) and with water until pH = 7. The organic layer was dried over MgSO4, filtrered and evaporated under reduced pressure. The crude product 7 (2.26 g, 72%) was used without further purification. Yellow powder. Rf; 0.38 (CH2Cl2/MeOH 9/1). 
3,6-Anhydro-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-(4methylbenzenesulfonate)-L-galacto-heptonamide 8
To a solution of 7 (1.94 g, 5.2 mmol) in CH2Cl2 (50 mL) were added Et3N (1.8 mL, 13 mmol, 2.5 eq.), DMAP (61 mg, 0.5 mmol, 0.1 eq.) and tosyl chloride (2 g, 10.4 mmol, 2 eq.) and the mixture was stirred for 24 h at room temperature. The solution was washed with 1N HCl (20 mL), sat. aq. NaHCO3 (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, filtered and the solvent was evaporated in vacuo. 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[3-[[(phenylmethoxy)carbonyl]amino]propyl]amino]-L-galacto-heptonamide 9
A solution of 8 (422 mg, 0.8 mmol, 1 eq.) and amine (0.8 mmol, 4 eq.) in isopropanol (4 mL) was heated at 100°C for 48h in a sealed tube. The solvent was removed under reduced pressure and the residue was diluted with EtOAc (10 mL) and washed with sat. aq. NaHCO3 (2x5 mL). The organic layer was dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography (silica gel, cyH/EA) to provide 9 (324 mg, 72%). Colorless gum. Rf; 0.33 (CH2Cl2/MeOH 9/1). 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[4-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-L-galacto-heptonamide 10
Prepared starting from 8 (422 mg, 0.8 mmol) following procedure described for 9. Yield: 70% (323 mg). 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[N-[bis[(phenylmethoxy)carbonyl]]aminoiminomethyl]-N-[3-[bis[(phenylmethoxy)carbonyl]]guanidinopropyl]amino]-L-galacto-heptonamide 12
To a solution of 9 (282 mg, 0.5 mmol) in MeOH (10 mL) was added Pd/C (10%) (30 mg, 10% w/w). After stirring under H2 atmosphere (30 psi) until completion of the reaction, the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The crude was solubilized in DMF (3 mL) and N,N'-bis(dibenzyloxycarbonyl)-S-methylisothiourea (1.0 mmol, 2eq.), HgCl2 (134 mg, 0.5 mmol, 1 eq.) and Et3N (153 mg, 1.5 mmol, 3 eq.) were added under argon atmosphere. After stirring 14 h at room temperature, the solvent was removed in vacuo and the residue was dissolved in EtOAc (40 mL). The organic layer was washed with water (5 mL), brine (5 mL), dried over MgSO4, filtered and the solvent was removed under reduced pressure. The compound was purified by column chromatography (silica gel, cyH/EA) to provide 12 (131 mg, 25%).White solid. Rf; 0.52 (EA). 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[N-(aminoiminomethyl)-N-(5-guanidinopentyl)amino]-L-galacto-heptonamide 17
Prepared starting from 14 (160 mg, 0.15 mmol) following procedure described for the synthesis of 15. 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-7-O-acetyl-D-altro-heptoanic acid methyl ester 18
To a stirred solution of 3 (2.5 g, 8.7 mmol) in EtOAc (20 mL) was added Pd/C (10%) (1 g, 40% w/w). The mixture was stirred under H2 atmosphere (30 psi) for 18h. The reaction mixture was then filtered through a pad of celite and the solvent was removed in vacuo. The compound was purified by column chromatography (silica gel, cyH/EA) to provide 18 (2.1 g, 85%). 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-D-altro-heptonic acid methyl ester 19
To a stirred solution of 18 (2.0 g, 6.9 mmol) in methanol (50 mL) was added a catalytic amount of sodium at 0°C under argon atmosphere. After completion of the reaction (approx. 1h), acidic resin Amberlite IR-120 was added until pH = 4. After filtration, the solvent was removed under reduced pressure to provide 19 (1.65 g, 97%). Colorless gum. Rf; 0.10 (cH/EA: 2/1). 
3,6-Anhydro-2-deoxy-7-O-[(tert-butyldimethyl)silyl]-4,5-O-(1-methylethylidene)-Daltro-heptonic acid methyl ester 20
To a solution of 19 (1.5 g, 6.1 mmol, 1 eq.) in DMF (12 mL), were added tertbutyldimethylsilyl chloride (1.1g, 6.71 mmol, 1.1 eq.) and imidazole (1.04 g, 15.25 mmol, 2.5 eq.) and the mixture was stirred at room temperature until completion of the reaction. The reaction was quenched by addition of EtOH and the solvent were removed in vacuo. The residue was diluted in EtOAc (40 mL) and washed with water (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The compound was purified by column chromatography (silica gel, cyH/EA) to provide 20 in quantitative yield (2. 
3,6-Anhydro-7-O-[(tert-butyldimethyl)silyl]-2-deoxy-4,5-O-(1-methylethylidene)-Daltro-heptonic acid 21
To a solution of 20 (500 mg, 1.39 mmol) in THF (15 mL) and water (5 mL) was added LiOH (100 mg, 4.17 mmol, 3 eq.) and the mixture was stirred until completion of the reaction monitored by tlc. THF was removed under reduced pressure, CH2Cl2 (20 mL) was added and the pH was adjusted to [2] [3] 
3,6-anhydro-7-O-[(tert-butyldimethyl)silyl]-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-D-altro-heptonamide 22
To a stirred solution of 21 (260 mg, 0.75 mmol, 1 eq.) in CH2Cl2 (10 mL) were added tryptamine (132 mg, 0.83 mmol, 1.1 eq.) and EDC (159 mg, 0.83 mmol, 1.1 eq.) at 0°C under argon atmosphere. After stirring overnight at room temperature, the solvent was evaporated under reduced pressure. The residue was diluted with CH2Cl2 (20 mL) and the organic layer was washed with a saturated aqueous solution of NaHCO3 (10 mL), dried over MgSO4, filtered and the solvent was removed in vacuo. The product was purified by column chromatography (silica gel, cyH/EA) to provide 22 (292 mg, 80%). Colorless gum. Rf; 0.75 (CH2Cl2/MeOH 9/1). 
3,6-Anhydro-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-D-altroheptonamide 23
To a solution of 22 (248 mg, 0.51 mmol, 1 eq.) in dry THF (3 mL) was added dropwise TBAF (1M in THF) (0.77 mL, 0.77 mmol, 1.5 eq.) at 0°C and the reaction mixture was stirred overnight under argon atmosphere. Water (5 mL) was added and the aqueous layer was extracted with EtOAc (2x15 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO4, filtered and the solvent was removed in vacuo. The product was purified by flash chromatography (silica gel, cyH/EA) to provide 23 (181 mg, 95%). Colorless gum. Rf; 0.61 (CH2Cl2/MeOH 9/1). [α]D= -6.3 (c = 0.09, CHCl3). 1 
3,6-Anhydro-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-7-(4-methylbenzenesulfonate)-4,5-O-(1-methylethylidene)-D-altro-heptonamide 24
Prepared starting from 23 (160 mg, 0.43 mmol) following procedure described for 8. 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[2-[[(phenylmethoxy)carbonyl]amino]ethyl]amino]-D-altro-heptonamide 25
Prepared starting from 24 (170 mg, 0.32 mmol) following procedure described for 9. Yield: 82% (144 mg). 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[N-[bis[(phenylmethoxy)carbonyl]]aminoiminomethyl]-N-[2-[bis[(phenylmethoxy)carbonyl]]guanidinoethyl]amino]-D-altro-heptonamide 26
Prepared starting from 25 (120 mg, 0.22 mmol) following procedure described for 12. Yield: 30% (68 mg). White solid. Rf; 0.50 (EA). 
3,6-anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[N-(aminoiminomethyl)-N-(2-guanidinoethyl)amino]-D-altro-heptonamide 27
Prepared starting from 26 (50 mg, 0.05 mmol) following procedure described for the synthesis of 15. Yield: 90% (20 mg 
N,N'-[Bis(phenylmethoxy)carbonyl]-N''-(but-3-ynyl)-guanidine 28
To a cooled solution of butyn-4-ol (151 µL, 2.0 mmol, 1 eq.), N,N'bis(benzyloxycarbonyl)guanidine (650 mg, 2.0 mmol, 1 eq.) and PPh3 (630 mg, 2.4 mmol, 1.2 eq.) in dry toluene (10 mL), was added dropwise over 5 minutes a solution of diethylazodicarboxylate (DEAD, 378 µL, 2.4 mmol, 1.2 eq.) in toluene (5 mL) under argon atmosphere. The mixture was stirred at room temperature for 4h and the solvent was removed in vacuo. 
N,N'-[Bis(phenylmethoxy)carbonyl]-N''-(pent-4-ynyl)-guanidine 29
Prepared starting from pentyn-5-ol (185 µL, 2.0 mmol) following procedure described for 28. Yield: 89% (700 mg). Colorless oil. Rf; 0.75 (cH/EA: 8/2). 1 H NMR (250 MHz, CDCl3): δ = 1.78-1.90 (m, 3H, CH2, C≡C-H), 2.19 (td, 2H, J = 7.0, J = 7.0 Hz, CH2), 4.10 (t, 2H, CH2), 5.16 (s, 2H, CH2-Ph), 5.25 (s, 2H, CH2-Ph), 7. 28-7.42 (m, 10H, 10 H-Ar), 9.28 (br s, 1H, NH), 9.44 (br s, 1H, NH). 13 
3,6-Anhydro-7-azido-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1methylethylidene)-L-galacto-heptonamide 30
To a solution of 8 (1.0 g, 1.9 mmol) in DMF (10 mL) was added sodium azide (1.0 g, 15.2 mmol, 8 eq.) and the mixture was stirred for 2 days at 80°C. The solvent was removed in vacuo and the residue was diluted with EtOAc (50 mL) and washed with H2O (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[4-[2-[N-[bis(phenylmethoxy)carbonyl]]guanidinoethyl]-1H-1,2,3-triazol-1-yl] 
3,6-
-L-galactoheptonamide 31
To a solution of 30 (300 mg, 0.75 mmol, 1 eq.) and 28 (284 mg, 0.75 mmol, 1 eq.) in CH2Cl2 (4 mL) were added H2O (4 mL), CuSO4,5H2O (8 mg, 0.04 mmol, 0.05 eq.) and sodium ascorbate (15 mg, 0.075 mmol, 0.1 eq.). After completion of the reaction, the solution mixture was diluted with water and CH2Cl2 (20 mL) and the layers were separated. The aqueous layer was washed with CH2Cl2 (2x20 mL) and the combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure. The compound was purified by column chromatography (silica gel, cyH/EA) to provide 31 (466 mg, 80%). White solid. Rf; 0.46 (EA). 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[4-[3-[N-[bis(phenylmethoxy)carbonyl]]guanidinopropyl]-1H-1,2,3-triazol-1-yl]-L-galactoheptonamide 32
Prepared starting from 30 (300 mg, 0.75 mmol) following procedure described for 31. Yield: 70% (415 mg). White solid. Rf; 0.43 (EA). 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[4-(2-guanidinoethyl)-1H-1,2,3-triazol-1-yl]-L-galacto-heptonamide 33
Prepared starting from 31 (150 mg, 0.19 mmol) following procedure described for 15. Yield: 90% (87 mg). White solid. Rf; 0.0 (EA). HPLC (60/40): tR = 5.401 min.
[α] D= -11 .9° (c = 0.2, MeOH). Mp = 138°C. 1 H NMR (400 MHz, MeOH-d4): δ = 1.32 (s, 3H, C(CH3)), 1.50 (s, 3H, C(CH3)), 2.55- 2.65 (m, 2H, H-2), 2.89-2.94 (m, 4H, H-8, H-β), 3.41-3.49 (m, 4H, H-9, H-α) , 3.87- 3.93 (m, 2H, H-3, H-6 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[4-(3-guanidinopropyl)-1H-1,2,3-triazol-1-yl]-L-galacto-heptonamide 34
Prepared starting from 32 (150 mg, 0.19 mmol) following procedure described for 15. Yield: 90% (90 mg). 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-7-[4-[2-[N-[bis(phenylmethoxy)carbonyl]]guanidinoethyl]-1H-1,2,3-triazol-1-yl]-L-galactoheptonamide 35
To a stirred solution of 31 (250 mg, 0.32 mmol) in H2O (2 ml) at 0°C was added trifluoroacetic acid (2 ml). After completion of the reaction (tlc monitoring), the solution mixture was diluted with EtOAc (50 mL) and NaHCO3 sat. aq. was added until pH 5-6. The product was extracted with EtOAc (2x15 ml) and the combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure. Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-7-[4-[3-[N-[bis(phenylmethoxy)carbonyl]]guanidinopropyl]-1H-1,2,3-triazol-1-yl] 
3,6-
-L-galactoheptonamide 36
Prepared starting from 32 (250 mg, 0.32 mmol) following procedure described for 35. Yield: 53% (127 mg). Colorless gum. Rf; 0.34 (EA/MeOH: 9/1). [α]D= -2.0° (c = 0.2, MeOH). 1 H NMR (250 MHz, MeOH-d4): δ = 1.82- 1.93 (m, 2H, H-9 ), 2. 47-2. 61 (m, 4H, H-2, H-8 
3,6-anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-7-[4-(3-guanidinopropyl)-1H-1,2,3-triazol-1-yl]-L-galacto-heptonamide 38
Prepared starting from 36 (100 mg, 0.13 mmol) following procedure described for 15. Yield: 95% (60 mg). 
N  -[2-C-[2,3:5,6-Bis-O-(1-methylethylidene)--D-gulofuranosyl]carboxymethyl)]-Lnitro-arginine methyl ester 39
To a solution of N  -NO2-L-arg-OMe (296 mg, 1.1 mmol, 1.1 eq.) and 5 (300 mg, 1 mmol, 1 eq.) in DMF (10 mL) were added HATU (570 mg, 1.5 mmol, 1.5 eq.) and DIEA (363 µL, 2.1 mmol, 2.1 eq.) at 0°C under argon atmosphere. After stirring at room temperature for 24h, the solvent was evaporated. The residue was dissolved in ethyl acetate (10 mL), washed with 1N HCl (5 mL), NaHCO3 sat. aq. (5 mL) and brine (5 mL). The organic layer was dried over MgSO4, filtered and concentrated. The product was purified by column chromatography (silica gel, cyclohexane/AcOEt) to provide 39 (258 mg, 50%). Colorless oil. Rf; 0.36 (CH2Cl2/MeOH: 9/1). 
N  -[2-C-[2,3:5,6-Bis-O-(1-methylethylidene)--D-gulofuranosyl]carboxymethyl)]-Larginine 40
To a solution of 39 (200 mg, 0.39 mmol) in THF (9 mL) and water (3 mL) was added LiOH (30 mg, 1.17 mmol, 3 eq.) and the mixture was stirred until completion of the reaction monitored by tlc. Amberlite ® IR-120 was added until pH = 3-4 and the mixture was filtered off. The solvent were evaporated and the obtained carboxylic acid was solubilized in MeOH (10 mL) and Pd/C (10%) (80 mg, 40% w/w) was added. After stirring under H2 atmosphere (40 psi) until completion of the reaction, the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. To a solution of 2 (630 mg, 2 mmol, 1 eq.) in pyridine (15 mL) was added LiI (2.6 g, 20 mmol, 10 eq.) and the mixture was stirred at 120 °C until completion of the reaction monitored by tlc. The solvent was removed under reduced pressure, CH2Cl2 (20 mL) was added and the pH was adjusted to 2-3 with 1N HCl. The layers were separated and the organic layer was washed with brine and dried over MgSO4, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, cyH/EA) to provide 41 (300 mg, 50%). White solid. Rf; 0.21 (cH/EA: 1/1). [α] D= -36 
Compound 42
To a solution of HCl.H-L-arg-OMe (191 mg, 0.73 mmol, 1.1 eq.) and 41 (200 mg, 0.67 mmol, 1 eq.) in DMF (10 mL) were added HATU (380 mg, 1.0 mmol, 1.5 eq.) and DIEA (243 µL, 1.41 mmol, 2.1 eq.) at 0°C under argon atmosphere. After stirring at room temperature for 24h, the solvent was evaporated. The crude product was solubilized in pyridine (15 mL), LiI (871 mg, 6.7 mmol, 10 eq.) was added and the mixture was stirred at 120 °C until completion of the reaction monitored by tlc. The solvent was removed under reduced pressure and the crude was 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-D-glycero-L-galacto-octonic acid methyl ester 43
To a stirred solution of 4 (3.16 g, 10.0 mmol) in methanol (200 mL) at 0°C was added an aqueous solution of 1N HCl (70 mL). After stirring at room temperature until completion of the reaction, sat. aq. NaHCO3 was added until pH = 7. Half of the solvent was removed under vacuo and the product was extracted with CH2Cl2 (3 x 100 mL). The organic layer was dried over MgSO4, filtered and the solvent was evaporated. The crude residue was purified by column chromatography (silica gel, cyH/EA) to provide 43 (2.54 g, 92%). White solid. Rf; 0.29 (EA). 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-L-galacto-heptonic acid methyl ester 44
To a stirred solution of 43 (2.2 g, 7.97 mmol) in methanol (180 mL) was added NaIO4 (3.42 g, 16.0 mmol, 2 eq.) under argon. After stirring at room temperature until completion of the reaction, the solvent was removed by half in vacuo. The mixture was diluted with CH2Cl2 (200 mL). The organic layer was washed with water (3 x 75 mL), dried over MgSO4, filtered and the solvent was removed under reduced pressure. The product was used without further purification.To a stirred solution of the obtained aldehyde in MeOH (190 mL) was added NaBH4 (305 mg, 7.97 mmol, 1 eq.) at 0°C. After 1 h at room temperature, the solvent was removed under reduced pressure. The residue was diluted in CH2Cl2 (100 mL) and the organic layer was washed with a solution of 1N HCl (30 mL) and with water until pH = 7. The organic layer was dried over MgSO4, filtrered and evaporated under reduced pressure. The crude product 44 was used without further purification. Yield: 93% (1.82 g). Colorless oil. Rf; 0.47 (EA). 
3,6-anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-benzosulfonylamino-L-galactoheptonic acid methyl ester 47
To a solution of 46 (500 mg, 1.84 mmol, 1 eq.) in MeOH (10 mL) was added Pd/C (10%) (50 mg, 10% w/w). After stirring under H2 atmosphere (15 psi) until completion of the reaction, the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The crude amine was solubilized in pyridine (3 mL) and this solution was added dropwise under argon atmosphere to a stirred solution of benzylsulfonyl chloride (282 µL, 2.21 mmol, 1.2 eq.) in pyridine (6 mL). After stirring at room temperature until completion of the reaction, the solvent was removed under reduced pressure. The residue was diluted with EtOAc (15 mL) and washed with H2O (2x5 mL). The organic layer was dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. 
3,6-anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-benzosulfonylamino-L-galactoheptonic acid 48
Prepared starting from 47 (500 mg, 1.30 mmol) following procedure described for 21. Yield: 90% (434 mg). Colorless gum. Rf; 0.10 (cH/EA: 1/2). 
N  -[2-C-[2,3-O-(1-methylethylidene)-5-benzosulfonylamino--Dgalactofuranosyl]carbonymethyl)]-L-arginine methyl ester 50
Prepared starting from 49 (500 mg, 0.85 mmol) following procedure described for 40. Yield: 82% (367 mg). White solid. Rf; 0.24 (H2O/MeOH: 1/1). HPLC (70/30): tR = 6.049 min. 
3,6-Anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-[[(4bromomethyl)benzo]sulfonylamino]-D-altro-heptonic acid methyl ester 57
To a solution of 52 (165 mg, 0.6 mmol, 1.0 eq.) in MeOH (10 mL) was added Pd/C (10%) (17 mg, 10% w/w). After stirring under H2 atmosphere (15 psi) until completion of the reaction, the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The crude amine was solubilized in CH2Cl2 (1.5 mL) under argon and pyridine (165 µL, 2.1 mmol, 3.5 eq.) and (4-bromomethylbenzyl)sulfonyl chloride (178 mg, 0.66 mmol, 1.1 eq.) were added dropwise. After stirring at room temperature for 30 min, the mixture was diluted with CH2Cl2 (10 mL) and washed with 1N HCl (2x5 mL). The organic layer was dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography (silica gel, cyH/EA) to provide 57 (174 mg, 61%). Colorless oil. Rf; 0.43 (cH/EA: 1/1). 
3,6-Anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-[[(4azidomethyl)benzo]sulfonylamino]-D-altro-heptonic acid methyl ester 58
To a stirred solution of compound 57 (120 mg, 0.25 mmol, 1 eq.) in DMF (2 mL) was added sodium azide (97 mg, 1.5 mmol, 6 eq.) and the mixture was stirred for 15 hours at 60°C. The solvent was removed in vacuo and the residue was diluted with CH2Cl2 (10 mL), washed with H2O (5 mL) and brine (5 mL). The organic layer was dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. 
N  -[2-C-[2,3-O-(1-methylethylidene)-5-[[(4-azidomethyl)benzo]sulfonylamino]--Dribofuranosyl]carbonymethyl)]]-L-arginine methyl ester 60
To a solution of H-L-Arg-OMe.2HCl (55 mg, 0.21 mmol, 1.1 eq.) and 59 (80 mg, 0.19 mmol, 1 eq.) in DMF (10 mL) were added HATU (108 mg, 0.29 mmol, 1.5 eq.) and DIEA (105 µL, 0.61 mmol, 3.2 eq.) at 0°C under argon atmosphere. The reaction mixture was stirred overnight at room temperature and the solvent was evaporated. This crude product was solubilized in THF (3 mL) and water (1 mL) and LiOH (30 mg, 0.57 mmol, 3 eq.) was added. The mixture was stirred until completion of the reaction monitored by tlc. Amberlite ® IR-120 was added until pH = 3-4 and the mixture was filtered off. The solvent were evaporated and the product was purified by column chromatography (C-18 silica gel, H2O/MeOH) and lyophilized to provide 
Figure S1.
Ribbon view of the NRP-1 b1 dimer in the tetragonal crystal, where bicine interacts with residues of a symmetry related protein molecule. Symmetry code: -X+½, Y-½, -Z+¼. Some residues interacting with bicine and the Na + ion are shown.
The bicine molecule forms short H...H van der Waals contacts (d = 2.23 Å) with the symmetry related Gln218 side chain. The bicine carboxylate group is also making a salt bridge with the symmetry related Arg402.
The binding of bulky ligands in the cleft is not compatible with the formation of the present tetragonal crystals. The binding cleft is located too close to a symmetry related protein. The b1 domain of human NRP-1 bound with bulky molecule EG00229 crystallized actually in a different space group with two molecules in the asymmetric unit. 4 The bicine molecule was used as pH buffer at a concentration of 100mM in the conditions yielding crystals. The initial structure of the free protein 9 which was crystallized at pH 6 using MES buffer has only water molecules in the binding site. The proteinonly surface is shown at an electron density level of 0.01 e/Å 3 and colored according to atom types (oxygen: red, nitrogen: blue, carbon: grey, hydrogen: white). The water molecules are shown as red spheres and the Na + ion as a purple sphere. The image was created with MoProViewer. 15 The Na + ion is also stabilized in this position distant from Asp320 due to a second electrostatic interaction with the symmetry related carboxylate of Asp289 (d = 4.1 Å) Figure S3 : Effect of the different compounds (c = 50 µM) on HUVECs ability to migrate through a basement membrane matrix (invasion assay). The results are presented as mean ± standard error of the mean of the percentage of inviding cells with non treated cells used as reference, n=6 p<0.05 was considered to be statistically significant. tuf, tuftsin; beva, bevacizumab.
